文献速递肿瘤 PET/CT心脏核医学

成纤维细胞激活蛋白(FAP)特异性PET在非恶性适应症中的临床结果:系统综述

Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review.
PubMed 文献 · EJNMMI Res · 2021-02-19

FAP特异性PET已用于心脏成像、IgG4相关疾病、良性肿瘤及各类炎症;两项关于IgG4相关疾病的前瞻性研究显示其有潜力区分炎性与纤维化病变,有助于指导患者管理。结论指出多数文献限于病例报告和偶然发现,但针对IgG4相关疾病及心血管疾病的初步回顾性和前瞻性研究结果令人鼓舞,值得进一步研究。

要点

  • FAP特异性PET已用于心脏成像、IgG4相关疾病、良性肿瘤及各类炎症等非恶性适应症。
  • 两项前瞻性研究显示FAP特异性PET有潜力区分IgG4相关疾病的炎性与纤维化病变。
  • 现有证据多限于病例报告和偶然发现,但心血管疾病和IgG4相关疾病的研究结果值得进一步探索。

核心结论

  • FAP特异性PET在非恶性适应症中的文献多限于病例报告和偶然发现,但针对IgG4相关疾病及心血管疾病的初步研究结果令人鼓舞,值得进一步研究。

研究设计与样本

  • 系统综述,检索MEDLINE数据库,按PRISMA指南筛选文献,纳入包含非恶性疾病患者的FAP特异性PET临床研究。

主要发现

  • FAP特异性PET已应用于心脏成像、IgG4相关疾病、良性肿瘤及各类炎症。
  • 两项关于IgG4相关疾病的前瞻性研究显示FAP特异性PET有潜力区分炎性与纤维化病变,可用于指导患者管理。

临床怎么用

  • FAP特异性PET在IgG4相关疾病中可能有助于区分炎性与纤维化病变,从而辅助临床管理决策。

局限性

  • 关于FAP特异性PET用于非恶性适应症的发表文献大多限于病例报告和偶然发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Small molecules targeting fibroblast activation protein (FAP) have emerged as a new group of tracers for positron emission tomography (PET) in 2018. While most of the existing literature has been focussed on the application of FAP-specific PET in various kinds of cancers, some researchers have, both intentionally or unintentionally, used FAP-specific PET in patients with non-cancerous diseases. The purpose of this systematic review is therefore to summarize the available evidence of FAP-specific PET for non-malignant indications. METHODS: The MEDLINE database was searched for studies presenting the clinical use of FAP-specific PET, the records were screened according to PRISMA guidelines and articles containing patients suffering from non-malignant diseases were included. RESULTS: Sixteen studies with 303 patients were included. FAP-specific PET has been used in cardiac imaging, IgG4-related disease, benign tumors as well as various kinds of inflammation. Two prospective studies on FAP-specific PET for IgG4-related disease show its potential to differentiate inflammatory from fibrotic lesions, which could be used to determine the management of these patients. CONCLUSION: While publications on FAP-specific PET for non-malignant indications are mostly limited to case reports and incidental findings, the first retrospective and prospective studies present promising results for IgG4-related as well as cardiovascular disease that warrant further research. Several currently recruiting trials will add to the body evidence in the next few years.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Windisch P, Zwahlen DR, Giesel FL, et al. Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review. EJNMMI Res. 2021. PMID: 33606104. doi:10.1186/s13550-021-00761-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。